May 14, 2015 • 8:05 am EDT Corbus Pharmaceuticals Appoints Charles N. Serhan, Ph.D., to Scientific Advisory Board
May 13, 2015 • 7:05 am EDT Corbus Pharmaceuticals Reports 2015 First Quarter Financial Results and Provides Business Update
May 4, 2015 • 7:05 am EDT Corbus Pharmaceuticals to Present at the Cystic Fibrosis Workshop Hosted by JMP Securities on May 8, 2015
Apr 22, 2015 • 7:05 am EDT Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab™ Clinical Program
Apr 16, 2015 • 7:35 am EDT Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
Apr 1, 2015 • 8:00 am EDT Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab™ in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
Mar 9, 2015 • 8:35 am EDT Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab™
Feb 11, 2015 • 7:35 am EST Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015